Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Net Income (2020 - 2025)

Historic Net Income for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$12.2 million.

  • Ovid Therapeutics' Net Income rose 1319.43% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.3 million, marking a year-over-year decrease of 1178.12%. This contributed to the annual value of -$26.4 million for FY2024, which is 4949.66% up from last year.
  • According to the latest figures from Q3 2025, Ovid Therapeutics' Net Income is -$12.2 million, which was up 1319.43% from -$4.7 million recorded in Q2 2025.
  • Ovid Therapeutics' 5-year Net Income high stood at $176.0 million for Q1 2021, and its period low was -$26.0 million during Q4 2021.
  • For the 5-year period, Ovid Therapeutics' Net Income averaged around -$2.0 million, with its median value being -$12.0 million (2022).
  • As far as peak fluctuations go, Ovid Therapeutics' Net Income soared by 97871.45% in 2021, and later tumbled by 15497.01% in 2025.
  • Ovid Therapeutics' Net Income (Quarter) stood at -$26.0 million in 2021, then skyrocketed by 55.75% to -$11.5 million in 2022, then crashed by 33.18% to -$15.3 million in 2023, then surged by 39.61% to -$9.3 million in 2024, then tumbled by 31.4% to -$12.2 million in 2025.
  • Its Net Income stands at -$12.2 million for Q3 2025, versus -$4.7 million for Q2 2025 and -$10.2 million for Q1 2025.